Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction
- 1 November 2003
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 92 (9) , 19-25
- https://doi.org/10.1016/s0002-9149(03)00828-2
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trialUrology, 2003
- Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated AnalysesJournal of Urology, 2002
- Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction.World Journal of Urology, 2001
- On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunctionInternational Journal Of Impotence Research, 2001
- Phosphodiesterase 5 inhibitors and nitrergic transmission—from zaprinast to sildenafilEuropean Journal of Pharmacology, 2001
- Erectile DysfunctionNew England Journal of Medicine, 2000
- Cyclic GMP Phosphodiesterase-5: Target of SildenafilJournal of Biological Chemistry, 1999
- The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology, 1997
- Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.Journal of Clinical Investigation, 1990
- Impaired Neurogenic and Endothelium-Mediated Relaxation of Penile Smooth Muscle from Diabetic Men with ImpotenceNew England Journal of Medicine, 1989